Flerie Insights

In recent decades, the prevalence of obesity has increased dramatically worldwide, posing serious challenges to public health, but traditional definitions and treatments for obesity often fall short. As science moves beyond weight loss there is a shift toward understanding obesity as a complex, chronic disease with diverse causes and responses to treatment.

In this episode, Dr. Ted Fjällman speaks with Professor Carel le Roux about the evolving landscape of obesity care, exploring current and future treatment options, common misconceptions, and highlighting the importance of treating the disease of obesity rather than only focusing on weight loss.

Professor le Roux is an eminent leader in the fast-changing fields of obesity and diabetes and his views are not only timely for practicing clinicians but for anyone investing their time or money in diabesity.

Heart failure is a growing global health challenge, yet significant gaps remain in its treatment. With millions of patients suffering from reduced quality of life and high mortality rates, there is an urgent need to innovate and transform care pathways.

In this episode, Dr. Ted Fjällman and Professor Lars Lund, discuss the critical gaps in the treatment of heart failure. They discuss recent advancements, the challenges facing patients and clinicians, and the potential for innovative therapies to transform care and improve outcomes for millions affected worldwide.

Professor Lund is a shareholder in AnaCardio.

The past few years have been challenging for many life science companies, both in the private setting but also those on public markets, and the IPO window for new listings has been essentially closed. The industry is dependent on the availability of capital as well as the risk appetite, both impacted by macroeconomic factors. Deal-making and M&A (merges and acquisitions) with pharma are the lifeblood of the industry.

In this episode, Ted Fjällman speaks to Tim Opler. Having taken part in more than 150 transactions with a total value of $100 billion, Tim shares his expertise and elaborates on different ways of financing innovation, a booming obesity field, and how patents are currently central to gaining a competitive advantage, but not the only measure.

Prostate cancer remains one of the most prevalent and costly cancers globally, posing challenges for both early detection and effective management. The healthcare burden continues to rise as more patients require advanced therapies and long-term care.

In this episode, Dr. Ted Fjällman and Professor Henrik Grönberg, delve into the rising healthcare burden of prostate cancer. They discuss breakthroughs in research, emerging treatment strategies, and how these developments can address the challenges in detection, management, and long-term care to improve patient lives.

Professor Grönberg is a shareholder in A3P Biomedical

Pain is a universal human experience and a protective mechanism with which the body responds to harmful stimuli. It is a complex physiological process whereby pain receptors send electrical signals via the nervous system to the brain, which will ultimately lead to the perception of pain. However, it can also be destructive when the internal regulatory processes fail. The ongoing opioid crisis highlights the scale of the problem, as well as some of the issues and shortfalls of medical management.

In this episode, Ted Fjällman speaks to Frank Huygen, a clinician and researcher that has dedicated his life to better understanding the field and to serve patients suffering from complex pain conditions. They cover several fascinating areas, including the increasingly recognised inflammatory component of the pain process, remaining areas of unmet need, and how it is a subjective and highly personal experience requiring tailored treatments.